Devonian Health Gets Health Canada Approval for Thykamine Radiodermatitis Trial

• Devonian Health Group received Health Canada authorization for a 150-patient trial of Thykamine 0.1% to prevent radiation-induced skin injury.
• The randomized, double-blind study will compare the topical formulation with Glaxal Base cream in women undergoing breast cancer radiotherapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Devonian Health Group Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610200845PR_NEWS_USPR_____MO75893) on October 20, 2026, and is solely responsible for the information contained therein.